¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸ CKD-MBD ¿¬±¸È¸ ¿¬¼ö°Á : 2023-09-10 |
|
¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸ CKD-MBD ¿¬±¸È¸ ¿¬¼ö°Á : 2023-09-10 ±³À°ÁÖÁ¦ : CKD-MBD ¿¬±¸È¸ ¿¬¼ö°Á ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ À̸ÞÀÏ : ksn@ksn.or.kr ±³À°Á¾·ù : ³»°ú Âü¼®¿¹»óÀÎ : 250¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 40,000¿ø ºñ°í Àü¹®ÀÇ 3¸¸¿ø, ÀüÀÓÀÇ ¹× Àü°øÀÇ 2¸¸¿ø, °£È£»ç 1¸¸¿ø, ´çÀϵî·Ï : Àü¹®ÀÇ 4¸¸¿ø, ±×¿Ü 3¸¸¿ø
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 08:30~09:00 Parathyroid gland in Health °µ¿Çõ(ºÎõ ¼º¸ðº´¿ø) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:00~09:20 Parathyroid cell proliferation in Disease; Primary vs. Secondary Á¤°æõ(¼¿ï´ëº´¿ø º´¸®°ú) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:20~09:50 Consequences of Hyperparathyroidism - mineral, bone, extra skeletal Á¤Áö¿ë(°¡Ãµ±æº´¿ø) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:50~10:20 Differential diagnosis in Primary hyperparathyroidism in CKD Á¶¾ÆÁø(ÇѸ²´ë °³²¼º½Éº´¿ø) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 10:20~10:50 Imaging for Hyperparathyroidism; Primary vs. Secondary ÃÖÇýÁ¤(ºÐ´çÂ÷º´¿ø ¿µ»óÀÇÇаú ) ÈÞ½Ä 09¿ù 10ÀÏ ´ë°´ç 10:50~11:10 Break () ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 11:10~11:35 Additive beneficial effects of GLP-1 agonist in CKD [IV & oral] ±èÁ°æ(ÆòÃÌ ÇѸ²´ëº´¿ø) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 11:35~12:00 Additive beneficial effects of mineralocorticoid receptor antagonist in CKD ÃÖÀ¯Á¤(°í´ë±¸·Îº´¿ø ¼øȯ±â) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:00~12:20 Primary hyperparathyroidism Guideline 2022 È«¾Æ¶÷(ȼøÀü³²ÀÇ´ë) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:20~12:50 Surgery vs. Radiofrequency Ablation ±è¿ì¿µ(°í´ë±¸·Îº´¿ø) ±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:50~13:30 VDRAs, Cinacalcet, Evocalcet, Etelcalcetide & Upacicalcet in Secondary hyperparathyroidism ¾È½Å¿µ(°í´ë±¸·Îº´¿ø)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|